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Atherosclerotic disease of the subclavian artery
can be asymptomatic or may produce various com-
binations of symptoms related to posterior cerebral
ischemia or upper extremity ischemia. Intervention
may be indicated when such symptoms occur.
Management of subclavian artery occlusive disease
Carotid-subclavian bypass grafting with
polytetrafluoroethylene grafts for
symptomatic subclavian artery stenosis or
occlusion: A 20-year experience
Ali F. AbuRahma, MD,a Patrick A. Robinson, MD,b and Tucker G. Jennings,
MD,a Charleston, WVa, and Ridgefield, Conn
Background and Purpose: Since the advent of subclavian artery percutaneous translumi-
nal angioplasty/stenting, several authorities advocate it as the treatment of choice for
patients with subclavian artery disease, claiming results equal to or better than those of
reconstructive vascular surgery. However, most of their quoted surgical series included
patients who may have other brachiocephalic disease who were treated nonuniformly by
means of various bypass grafts with different grafts in the same series (eg, Dacron, poly-
tetrafluoroethylene [PTFE], or vein). In this study, we analyze the long-term results of
a large series of carotid-subclavian bypass grafts for subclavian artery disease in which
PTFE was uniformly used; the study can be used as a future reference to compare the
results of subclavian artery percutaneous transluminal angioplasty/stenting.
Patient Population and Methods: Fifty-one patients with symptomatic subclavian artery
disease (40 occlusions and 11 stenoses) who were treated with carotid-subclavian bypass
grafts (PTFE [Goretex]) during a 20-year period were analyzed. Graft patency was
determined clinically and confirmed with Doppler scanning pressures and duplex ultra-
sound scanning. The cumulative patency, overall survival, and symptom-free survival
rates were calculated with the life table method.
Results: Indications for surgery were arm ischemia in 34 patients (67%), vertebrobasilar
insufficiency (VBI) in 27 (53%), and symptomatic subclavian steal in 7 (14%). A combi-
nation of arm ischemia and VBI occurred in 17 (33%) of these patients. The mean follow-
up was 7.7 years with a median of 7.0 years (range, 1-19 years). The 30-day morbidity rate
was 6%, with no perioperative stroke or mortality. Immediate relief of symptoms was
achieved in 100% of patients; however, four patients (8%) had late recurrent symptoms
(three with VBI). The primary patency and secondary patency rates at 1, 3, 5, and 10 years
were 100%, 98%, 96%, and 92% and 100%, 98%, 98%, and 95%, respectively. The symptom-
free survival rates at 1, 3, 5, and 10 years were 100%, 96%, 82%, and 47%, respectively. The
overall survival rates at 1, 3, 5, and 10 years were 100%, 98%, 86%, and 57%. The mean
hospital stay was 3.5 days in the late 70s and 80s and 2.1 days in the 90s (P < .001).
Conclusions: Carotid-subclavian bypass grafts with PTFE grafts for subclavian artery dis-
ease are safe, effective, and durable and should remain the procedure of choice, particu-
larly in good-risk patients. (J Vasc Surg 2000;32:411-9.)
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has evolved a great deal over the years, and a variety
of therapeutic options are available. Debakey et al1
first reported successful revascularization of innomi-
nate and subclavian arteries via a transthoracic
approach in 1958. Diethrich et al2 subsequently
introduced the carotid-subclavian bypass graft in
1967 as the first extrathoracic approach. Several stud-
ies have shown that the durability and efficacy of this
technique and the carotid-subclavian transposition are
comparable to the transthoracic approach with much
less operative mortality and morbidity.3-9
Percutaneous transluminal angioplasty (PTA) with
or without stenting of the subclavian artery provides
another tool for those treating patients who have
stenosis or occlusion. The first reported case of subcla-
vian artery angioplasty was by Bachman and Kim10 in
1980. Subclavian artery PTA/stenting is now com-
monly used by some for treating subclavian artery
stenosis, and certain authorities advocate it as the first
line of therapy or treatment of choice for this dis-
ease.11-16 In this study, we analyze the largest long-
term series of carotid-subclavian bypass grafts for sub-
clavian artery stenosis or occlusion in which polytetra-
fluoroethylene (PTFE) was uniformly used in North
America; this can be used for future reference to com-
pare the results of subclavian artery PTA/stenting.
PATIENT POPULATION AND METHODS
One hundred nine patients underwent carotid-
subclavian bypass grafts in which PTFE grafts were
used (Goretex; W. L. Gore and Associates, Inc,
Flagstaff, Ariz) between July 1978 and June 1998
(20 years) for both symptomatic subclavian artery
disease and common carotid artery disease. In this
study, we analyze 51 of these patients with isolated
symptomatic subclavian artery disease. Patients with
innominate lesions or combined carotid and subcla-
vian artery disease or patients who may need complex
reconstruction were excluded. All patients had a
patent and normal vertebral artery at the side of the
subclavian artery disease, and 22 of 27 patients with
vertebrobasilar insufficiency (VBI) had hypoplastic or
diseased contralateral vertebral arteries that were not
suitable for vertebral artery reconstruction.
The hospital records were reviewed to determine
the demographic data, risk factors, presenting clinical
manifestation, the location of the subclavian artery
stenosis or occlusion, and immediate postoperative
results. Indications for surgery were classified into
arm ischemia (claudication, rest pain, or trophic
changes), symptomatic subclavian steal, or VBI
(including dizziness, drop attacks, blackout spells,
blurred vision, diplopia, ataxia, and vertigo). All
patients with VBI had at least two or more of these
symptoms; therefore, no patients had surgery for the
isolated symptom of dizziness. Patients with VBI or
symptomatic subclavian steal were also evaluated for
operation by neurologists to rule out other causes of
their symptoms. Patients with subclavian steal gave a
classic history of VBI on arm exertion and had retro-
grade vertebral flow documented with duplex ultra-
sound scanning and angiography. All patients had
preoperative arm Doppler scanning pressures with
pressure gradient measurements. They also had four-
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Fig 1. Kaplan-Meier graph showing time to loss of primary patency.
vessel arch aortography with carotid and subclavian
arteriography before surgery. All operations were
performed while the patients were under general
anesthesia, and 6- or 8-mm PTFE grafts were used.
Follow-up information was obtained from direct
office evaluation and the vascular laboratory data. Graft
patency was determined by the presence or absence of
peripheral arterial pulses and confirmed by the seg-
mental arm Doppler scanning pressures and duplex
ultrasound scan examinations that were done every 6 to
12 months. All patients with recurrent symptoms
underwent a duplex ultrasound scan and angiography
at the time of the symptoms’ recurrence. The cumula-
tive patency rates, overall survival rates, symptom-free
survival rates, and rates of freedom from symptom
recurrence were calculated with the life table method.
RESULTS
The mean follow-up in this series was 7.7 years
(range, 1-19 years). Table I summarizes the demo-
graphic data. Forty patients had subclavian artery
occlusion (78%), and 11 had stenoses (22%). Forty-
four lesions were located on the left side (86%), and
seven were located on the right side (14%). Table II
summarizes the indications for surgery with arm
ischemia present in 34 (67%) of 51 patients, VBI in 27
(53%), and symptomatic subclavian steal in 7 (14%).
As shown in this table, one indication for surgery was
present in 34 (67%) of 51 patients, and two indications
were present in 17 (33%) of 51 patients.
Early (30-day) results. The 30-day morbidity
rate was 6% (3 of 51), with no perioperative stroke or
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Table I. Demographic data
Demographic No. Percentage
Sex (male) 29/51 57%
Smoking 38/51 75%
Diabetes mellitus 14/51 28%
Hypertension 26/51 51%
Hypercholesterolemia 14/51 28%
Coronary artery disease 21/51 41%
Subclavian artery occlusion 40/51 78%
Subclavian artery stenosis 11/51 22%
Left side 44/51 86%
Right side 7/51 14%
Mean age (y) 62 (range, 46-75)
Mean preoperative pressure gradient (mm Hg) 35 (range, 25-52)
Mean postoperative pressure gradient (mm Hg) 4.92 (range, –5 to 10)
Mean follow-up (y) 7.7 (range, 1-19)
Fig 2. Kaplan-Meier graph showing time to loss of secondary patency.
mortality. Three patients had early perioperative
complications, which included one postoperative
myocardial infarction. Two patients had phrenic
nerve palsy; both recovered within 3 to 6 months.
Immediate relief of symptoms was achieved in 100%
of patients, with an early graft success (30-day paten-
cy) of 100%. The mean preoperative arm pressure
gradient was 35.2 mm Hg with a mean postoperative
pressure gradient of 4.9 mm Hg.
Table III summarizes the number of days of hos-
pitalization. As noted, 8% of patients had 1 day and,
20% had 2 days of hospitalization. Most of the
patients who had surgery in the 1990s (14 of 20)
had no more than 2 days of hospitalization. The
mean hospital stay was 3.5 days in the late 1970s and
1980s (July 1978 to December 1989) and only 2.1
days in the 1990s (January 1990 to June 1998; P <
.001).
Late results. As indicated earlier, immediate
relief of symptoms was achieved in 100% of patients;
however, four patients (8%) had late recurrent symp-
toms. The preoperative indication for surgery in
three of these four patients was VBI with symptom
recurrence at 3, 5, and 9 years, and all had patent
grafts. The fourth patient had surgery for arm
ischemia with recurrence of symptoms and graft fail-
ure at 6 years. This patient refused further surgery.
Overall, 48 of 51 grafts stayed patent (primary
patency), one underwent a thrombectomy (sec-
ondary patency), and two failed (one patient refused
surgery and the other patient’s graft was revised to
carotid-axillary artery bypass graft). The two
patients whose grafts were revised were asympto-
matic at the time of the vascular consult; however,
both gave a history of coolness and tingling of the
hand and forearm that lasted for only 1 to 2 hours at
the time of their presentation to their primary care
physician. Their vascular workup showed throm-
bosed grafts. After discussing their options, they
chose to undergo thrombectomy because of their
fear of recurrent symptoms. One had a successful
thrombectomy, and the other had a thrombectomy
and revision of the carotid-subclavian bypass graft to
carotid-axillary bypass graft because of significant
stenosis at the subclavian site. Figs 1 and 2 show the
primary and secondary patency rates by means of the
Kaplan-Meier life table method. As noted, the pri-
mary patency and secondary patency rates at 1, 3, 5,
and 10 years were 100%, 98%, 96%, and 92% and
100%, 98%, 98%, and 95%, respectively. Fig 3 shows
the symptom-free survival rates, which were 100%,
96%, 82%, and 47%, at 1, 3, 5, and 10 years, respec-
tively. Fig 4 shows the overall survival rates, which
were 100%, 98%, 86%, and 57% at 1, 3, 5, and 10
years, respectively. Overall, 22 patients died by the
end of the follow-up: 13 (59%) died as a result of
myocardial infarction, 6 (27%) of malignancy, 1 (5%)
of stroke, 1 (5%) of pneumonia, and 1 of an
unknown cause. Fig 5 shows the time to symptom
recurrence. As noted, the rates of freedom from
symptom recurrence at 1, 3, 5, and 10 years were
100%, 98%, 95%, and 88%, respectively.
DISCUSSION
Although symptomatic subclavian artery disease
is relatively uncommon,8,9,17-19 it may represent a
significant disability and should be treated appropri-
ately to provide good and long-lasting results. The
procedure should be effective and durable with min-
imal complications.
Currently, extrathoracic revascularization (carotid-
subclavian bypass graft, subclavian-carotid trans-
position, axillary-to-axillary artery bypass graft) and 
percutaneous balloon angioplasty with or without
stenting have been advocated as the primary treat-
ments for symptomatic subclavian artery stenosis or
occlusion. However, most studies in which angioplas-
ty results are reported have indicated that the treat-
ment of stenoses yields results that are significantly
different from the treatment of occlusions.11
It is generally thought that carotid-subclavian
bypass graft and carotid-subclavian transposition
have emerged as the treatments of choice for symp-
tomatic proximal subclavian artery stenosis or occlu-
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Table II. Indications for surgery
No. Percentage
Indication
Arm ischemia 34 67%
VBI 27 53%
Symptomatic subclavian steal 7 14%
No. of indications for surgery
One of three indications 34 67%
Two of three indications 17 33%
Table III. Number of days of hospitalization
No. of days in hospital No. of patients Percentage
1 4 8%
2 10 20%
3 24 47%
4 11 21%
5 2 4%
sion.4,8,19-21 Most modern series in which the use of
the extrathoracic approach in symptomatic subcla-
vian artery disease is reported demonstrated durable
relief of symptoms, with mortality rates of 0% to 3%
and perioperative stroke rates of 0% to 5%.20
However, most of the literature has included
patients who may have had symptomatic brachio-
cephalic disease or carotid artery disease apart from
the subclavian artery stenosis or occlusion. These
patients were also treated nonuniformly with various
types of bypass grafts with the use of different grafts
in the same series.3-9,20-23 This is significant because
it is difficult to compare the effectiveness of carotid-
subclavian bypass graft with other alternative tech-
niques (PTA/stenting) when there is nonuniformity
in the type of procedure and conduit. Furthermore,
graft material appears to affect long-term patency.
Several studies have shown saphenous vein grafts to
perform inferiorly to prosthetic grafts in this loca-
tion. Ziomek et al6 showed a 5-year patency of 94%
for prosthetic grafts compared with 58% for vein
grafts in patients with carotid-subclavian bypass
graft. Some authorities have documented that
ringed PTFE is superior to Dacron or vein in terms
of durability.20,21 Law et al20 reported that of all the
different conduits used for carotid-subclavian bypass
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Fig 3. Kaplan-Meier graph showing symptom-free survival.
Fig 4. Kaplan-Meier graph showing overall survival rates.
grafts, PTFE demonstrated the best results with a 5-
year actuarial patency of 95.2% ± 4.6%, followed by
Dacron grafts at 83.9% ± 10.5%. Saphenous vein
grafts had the poorest long-term patency rate at
64.8% ± 16.5%. However, the differences were not
statistically significant, which was thought to be
because of the small sample size. Because of this
nonuniformity, we analyzed carotid-subclavian
bypass graft for the treatment of symptomatic sub-
clavian artery stenosis or occlusion using only PTFE
as the conduit.
The advent of PTA/stenting has created
increased enthusiasm and interest in treating subcla-
vian artery stenosis or occlusion with the use of this
percutaneous approach. This technique has been
advocated by some as the first line of therapy or the
treatment of choice for subclavian artery stenosis or
occlusion.11-16 They claim lower morbidity and
mortality and a shorter hospital stay, with a high suc-
cess rate. Our study takes strong issue with this
claim. Our results confirm that carotid-subclavian
bypass grafting with the use of PTFE grafts is safe,
effective, and durable.
In regard to safety, our 30-day morbidity rate
was 6% with no perioperative strokes or mortality. In
a recent study of stenting for atherosclerotic occlu-
sive disease of the subclavian artery, Rodriquez-
Lopez et al13 documented an 11% minor complica-
tion rate and a 4% major complication rate that
included subclavian artery dissection, axillary artery
thrombosis, and brachial artery thrombosis. One
patient had transient ischemic attacks the day of the
procedure. Millaire et al15 reported on their imme-
diate and late results in 50 patients who underwent
subclavian angioplasty. Angioplasty was successful in
90% of their patients. However, three (6%) cases of
thrombosis occurred because of the percutaneous
approach: one of the axillary artery, one of the
brachial artery, and one of the aorta, which required
an aortobifemoral bypass graft. In addition, compli-
cations occurred in two other (4%) unsuccessful
angioplasties: an ischemic stroke in one case and a
thrombosis of the dilated side, which required a sur-
gical bypass graft. This is a combined major periop-
erative complication rate of 10%.
In another recent study, Henry et al11 reported
that 103 (91%) of 113 lesions were successfully
treated with PTA; however, ten (53%) occlusions
could not be recanalized. Fifty-one stents were
implanted in 46 patients in this group. There were
three (3%) procedure complications: one transient
ischemic attack, one major fatal stroke, and one arte-
rial thrombosis (a 1% major stroke and death rate).
They also cited two hematomas at the femoral punc-
ture site without any significant consequences plus
an additional brachial thrombosis that required sur-
gical treatment (3% minor complication rate), with a
combined minor and major complication rate of 5%.
We also evaluated the efficacy of carotid-subcla-
vian bypass grafting with PTFE for symptomatic sub-
clavian artery stenosis or occlusion. Immediate relief
of symptoms was achieved in 100%, with 100% early
(30-day) graft patency. However, four patients had
late recurrent symptoms, three of whom presented
with VBI; all had patent grafts. The VBI symptoms in
one of these three patients was thought to result from
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Fig 5. Kaplan-Meier graph showing the time to symptom recurrence.
cardiac arrhythmias and to result from intracranial
small vessel disease in another patient. Initial technical
success rates in studies in which PTA/stenting was
used for subclavian artery stenosis or occlusion range
from 92% to 100%.11-13,24-26 Some of the failures that
occurred early on in these studies involved the inabil-
ity to cross total occlusions with a guidewire.24,26
Several other studies indicate that subclavian occlu-
sions were recanalized in only about half of the
cases.11,12,27-29 Seventy-eight percent of our patients
had subclavian artery occlusion instead of stenosis.
Durability is another important issue that was
addressed in our study. The primary and secondary
patency rates at 1, 3, 5, and 10 years were 100%,
98%, 96%, and 92% and 100%, 98%, 98%, and 95%,
respectively.
Long-term follow-up in patients who underwent
PTA and stenting for subclavian artery stenosis or
occlusion is limited in most reported series. The
reported primary patency rates in these patients
range from 73% to 87% at 4 years with secondary
patency rates ranging from 90% to 94%.11,13,14,24
Currently, there are no prospective randomized
data comparing angioplasty/stenting of the subcla-
vian artery with surgical bypass grafting in the treat-
ment of subclavian artery disease. However, in a
study by Farina et al,29 21 patients who underwent
PTA for proximal stenosis of the subclavian artery
were compared with 15 patients who underwent
carotid-subclavian reconstruction. The incidence of
procedural complications was similar. Although bet-
ter early results were achieved in patients who
underwent PTA (actuarial patency: PTA 91%,
surgery 87%) after dilatation, Farina et al observed a
continuous deterioration of the hemodynamic status
of the artery, which resulted from a high rate of late
restenosis (actuarial patency: PTA 54%, surgery
87%). It should be noted that they excluded patients
from this study with long stenoses (> 4 cm) and
those with complete occlusion of the subclavian
artery, which can easily be corrected surgically.
In an era of managed care, greater emphasis has
been placed on cost-effective treatment. Some
authorities cite financial advantages of PTA/stenting
over surgery with respect to length of hospital stay.
However, this may be balanced by the number of
restenosed subclavian arteries after PTA/stenting
that require another dilatation, hospital stay, or
both. Furthermore, our data show that in the 1990s,
patients treated with carotid-subclavian bypass graft-
ing had an average hospital stay of only 2.1 days with
several patients being discharged within 24 hours
postoperatively.
In conclusion, our experience with carotid-
subclavian bypass grafting for subclavian artery
stenosis or occlusion with PTFE grafts has shown it
to be very safe and effective, with excellent long-
term patency. It provided our patients with lasting
relief from their symptoms, and we think it is still the
treatment of choice for subclavian artery stenosis or
occlusion in good risk patients.
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DISCUSSION
Dr William H. Edwards, Sr (Nashville, Tenn). Dr
Snyder, Dr Seeger, members, and guests. I appreciate the
opportunity of being able to discuss Dr AbuRahma’s paper,
and I certainly appreciate his timely fashion of sending it to
me in order for my review.
He has undertaken a comparison of carotid subclavian
bypass grafts to angioplasty and stenting for subclavian
occlusive disease. Subclavian occlusive disease is rarely a life-
threatening condition and represents a small percentage of
patients presenting with cerebrovascular insufficiency. In
our practice it was approximately 6% of patients evaluated
for cerebral symptoms. This means few vascular surgeons
have the opportunity to see many of these patients and may
see even fewer as PTA and stenting increases. 
I will direct my remarks to the two issues presented by
Dr AbuRahma: bypass surgical operations for subclavian
occlusive disease and angioplasty. 
My early vascular training was at UCLA with Jack
Cannon and Wiley Barker, and I was introduced to
endarterectomy in the treatment of vascular lesions. When
I went to Houston, I worked with Dr DeBakey, and I was
introduced to the use of Dacron grafts for reconstruction
of occlusive disease. In 1957 when Dr Scott and Dr Cate
did the first combined subclavian and vertebral artery
for endarterectomy at Vanderbilt, I was present at that
operation. 
Early in my practice I used endarterectomy much
more frequently than intrathoracic bypass for proximal
subclavian occlusive lesions. Neither of these operations,
however, was much fun. I was not innovative enough to
realize that the ipsilateral carotid artery was begging to be
used to correct subclavian stenosis. Stanley Crawford did
that for us in the mid 1960s, improving the playing field. 
Dr AbuRahma has documented the demographics,
symptoms, and early and late results for his 51 patients
treated over a 20-year period at the Byrd Health Sciences
Center. It is, he believes, the largest carotid subclavian
bypass with the longest follow-up reported in North
America. This means we can compare these results with the
largest series of subclavian carotid transpositions with the
longest follow-up recorded: our series of 178 patients
reported 4 years ago with 25-year follow-up. When com-
pared with other series of extrathoracic bypass graft for
subclavian stenosis, Dr AbuRahma’s PTFE series has better
short- and long-term patencies than those series that use
Dacron, autogenous tissue, and/or PTFE. A major advan-
tage of transposition is the absence of any prosthetic mate-
rial. This overcomes the problems he described in the paper
as nonuniformity in the type of procedure and conduit.
The mortality in his series was 0% while ours was 1.1%. We
had one death from an arrhythmia, and we had one death
from septicemia from an infection that was not adequately
treated early on. The short- and mid-term patencies in
both transposition and bypass were 100%. Dr AbuRahma’s
series had three occlusions with patency restored by
thrombectomy in one and bypass in a second. The trans-
position series had one occlusion during the 25-year fol-
low-up because of occlusion from a lesion of the proximal
internal common carotid artery. A review of the literature
at the time of the publication of our transposition series
yielded only two additional reported failures in 453 cases of
transposition, a truly remarkable long-term patency rate. 
Lesions of the proximal subclavian artery are amenable
to treatment with PTA and stenting. There is no question
about that. The question is, can the procedures give results
that are comparable to bypass or transposition? Many series
have been reported, as Dr AbuRahma reported to us, with
good short-term patencies and morbidities from 10% to
20%. In a combined series of 423 PTAs for subclavian
innominate disease, there was a technical success rate in
92% and a recurrence rate of 19% at 5 years. One of the
complications reported more than once and discussed here
with the panel yesterday was rupture of the subclavian
artery. There is no question that the surgeon who has ever
handled a subclavian artery knows that it is a thin, delicate
artery that can be torn with minimal manipulation. With
that said, however, with a leap of faith and knowing as a
vascular surgeon that you can handle any subclavian artery,
transposition becomes a very nice operation. There are no
controlled or randomized series to compare PTA and sur-
gical intervention. Surgical correction is safe with low mor-
bidity and mortality rates approaching 0% and excellent
patencies with long-term relief of symptoms. 
As endovascular surgical techniques in the treatment of
atherosclerotic disease and other arteries have improved with
the advances in technology, ease of access, improved results,
and better understanding of the pathophysiology of the dis-
ease, so will PTA and stenting occur in subclavian occlusive
disease. Everyone performing vascular surgery must be sure
that they have the skills and the credentials to offer PTA and
stenting for those patients in whom it might be appropriate. 
Dr AbuRahma has reported an excellent, well-docu-
mented series of carotid subclavian bypass for sympto-
matic subclavian occlusive disease with long-term follow-
up and excellent results. I do not, however, agree with his
conclusion that it is the surgical operation of choice for
proximal subclavian lesion. Transposition of the subclavian
to the ipsilateral carotid gives somewhat better long-term
results, restores flow directly into the vertebral artery in
those patients with hindbrain symptoms, requires only one
suture line, removes completely the risk of embolic
ischemia, and, lastly, does not introduce a prosthetic into
the neck. I do agree that currently, PTA is not the proce-
dure to recommend to most patients. 
I have three questions for Dr AbuRahma. Since 34 of
your patients had arm ischemia, does it bother you that
you are leaving the potential source of emboli with a
bypass? By the same token, 27 patients had hindbrain
symptoms. Were these all due to complete subclavian
occlusions with retrograde vertebral flow, or were they
lesions in the proximal vertebral artery? Second, at what
point on the distal subclavian do you perform the distal
anastomosis? And lastly, what technique do you recom-
mend in the patient who has significant ipsilateral internal
carotid occlusive disease?
I enjoyed the presentation and congratulate the
authors on their paper. Thank you.
Dr Ali F. AbuRahma. Thank you, Dr Edwards, for
your nice comments and questions. It was not the purpose
of this paper to compare carotid subclavian bypass with
carotid transposition. There is no doubt that carotid trans-
position is a good procedure to do, but most of the quot-
ed series in the radiology or cardiology literature use the
term carotid subclavian bypass to compare PTA series.
What I am trying to say in this article is let’s have a uni-
form series using whatever you want (PTFE, Dacron, etc)
and compare these results with PTA and stenting for both
safety and durability. I agree with Dr Edwards: carotid
transposition in good hands is perhaps even better than
carotid subclavian using PTFE or Dacron. 
In terms of the patients with arm ischemia, if there was
any question, we felt it was embolic. These had suture lig-
ation proximal to the graft, and that was done in several of
our patients. 
In regard to the presence of internal carotid artery
stenosis, you will notice that this is a very uniform series
because we did not include these patients in the series, but
we have done close to probably two dozen of these over
the last 20 years, where we combined a carotid endarterec-
tomy with carotid-subclavian bypass. 
Dr Timothy Sullivan (Greenville, SC). Dr AbuRahma,
I very much enjoyed your paper. We reported in the
Journal of Vascular Surgery in 1998 on over 80 brachio-
cephalic interventions with angioplasty and primary stent-
ing. Our results indicated a patency rate of 84% at 4 years
including initial failures, those failures occurring with
complete occlusions of the subclavian artery. I would echo
your statement that as with most endovascular procedures,
including brachiocephalic interventions, the aortoiliac seg-
ment, and lower extremity interventions, surgical repair
remains the gold standard and is typically the treatment of
choice.
I have a question regarding patients with subclavian
stenosis and coronary steal syndrome. In our series, the
most common indication for intervention was in patients
with internal mammary steal, in patients who had had
coronary bypass typically to the LAD from the left inter-
nal mammary artery. Many of those patients actually pre-
sented with unstable coronary syndromes, and we felt that
angioplasty and stenting was a very reasonable alternative
in those patients (perhaps carried a lower morbidity and
mortality) and that it really did not burn any bridges—that
at a later date we could go ahead and perform a surgical
reconstruction. I would like to know if any of your
patients in your series presented with coronary steal syn-
drome and what your thoughts are regarding that. 
Dr AbuRahma. Thank you for your question. None of
the patients in this series had coronary steal, but I agree
with you that someone with coronary steal and proximal
lesion can be treated with PTA and stenting. As I indicat-
ed earlier, and I am emphasizing one more time, I am not
saying that PTA and stenting is not an option. 
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